



A NEW ERA IN MASH

How Disease-Specific
Therapies Are
Changing the Game
and Best Practices for
Clinical Integration

Resources

Guidelines

Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. *Hepatology*. 2025;81:312-320. doi:10.1097/HEP.0000000000001112

Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract*. 2022;28:528-562. doi:10.1016/j.eprac.2022.03.010

de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. *J Hepatol*. 2022;76:959-974. doi:10.1016/j.jhep.2021.12.022

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatol*. 2021;75:659-689. doi:10.1016/j.jhep.2021.05.025

European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic

liver disease (MASLD): executive summary. *Diabetologia*. 2024;67:2375-2392.
doi:10.1007/s00125-024-06196-3

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81:492-542.
doi:10.1016/j.jhep.2024.04.031

Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2021;161:1657-1669. doi:10.1053/j.gastro.2021.07.049

Noureddin M, Charlton MR, Harrison SA, et al. Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis. *Clin Gastroenterol Hepatol*. 2024;22:2367-2377. doi:10.1016/j.cgh.2024.07.003

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323

Patient Resources

American Liver Foundation: Nonalcoholic Fatty Liver Disease (NAFLD)
<https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/non-alcoholic-fatty-liver-disease/>

Fatty Liver Foundation (FLF)
<https://www.fattyliverfoundation.org/>

Global Liver Institute
<https://globalliver.org/>

Liver Education Advocates
<https://liveradvocates.org/>

Non-Alcoholic Fatty Liver Disease: A Patient Guideline
Francque SM, Marchesini G, Kautz A, et al. *JHEP Rep*. 2021;3:100322.
doi:10.1016/j.jhepr.2021.100322